Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Forecast & Target Price

View the latest analyst price targets and forecasts to stay informed on market expectations. Click here to open.

ALT

Altimmune Inc

Nov 27 • 04:00PM ET

8.73

Dollar change +0.30
Percentage change 3.56	%

Healthcare • Biotechnology • USA • NASD

Peers: NVAX INO VXRT XFOR ADMA AGEN BCRX ANIX DTIL AVIR

| Held by: IWM VTI XBI VXF IWO IWN VTWO VHT OZEM IWC

Scroll to Statements

Index	RUT	P/E	-	EPS (ttm)	-1.55	Insider Own	0.83%	Shs Outstand	70.68M	Perf Week	8.45%
Market Cap	620.92M	Forward P/E	-	EPS next Y	-1.15	Insider Trans	-2.55%	Shs Float	70.53M	Perf Month	18.61%
Income	-103.52M	PEG	-	EPS next Q	-0.35	Inst Own	56.16%	Short Float	32.38%	Perf Quarter	32.07%
Sales	0.05M	P/S	12418.40	EPS this Y	16.83%	Inst Trans	-7.27%	Short Ratio	8.34	Perf Half Y	24.36%
Book/sh	1.88	P/B	4.66	EPS next Y	16.51%	ROA	-65.84%	Short Interest	22.84M	Perf Year	180.71%
Cash/sh	1.96	P/C	4.45	EPS next 5Y	-	ROE	-72.96%	52W Range	2.76 - 14.84	Perf YTD	-22.40%
Dividend Est.	-	P/FCF	-	EPS past 5Y	35.74%	ROI	-76.77%	52W High	-41.17%	Beta	0.14
Dividend TTM	-	Quick Ratio	16.87	Sales past 5Y	115.21%	Gross Margin	-3928.85%	52W Low	216.30%	ATR (14)	0.78
Dividend Ex-Date	Jan 20, 2017	Current Ratio	16.87	EPS Y/Y TTM	-1.24%	Oper. Margin	-191365.38%	RSI (14)	60.20	Volatility	9.69% 10.77%
Employees	59	Debt/Eq	0.01	Sales Y/Y TTM	-81.36%	Profit Margin	-199076.92%	Recom	1.25	Target Price	21.25
Option/Short	Yes / Yes	LT Debt/Eq	0.01	EPS Q/Q	16.61%	Payout	-	Rel Volume	0.82	Prev Close	8.43
Sales Surprise	614.29%	EPS Surprise	10.26%	Sales Q/Q	-98.62%	Earnings	Nov 12 BMO	Avg Volume	2.74M	Price	8.73
SMA20	10.74%	SMA50	21.77%	SMA200	15.47%	Trades		Volume	2,241,089	Change	3.56%

Date	Action	Analyst	Rating Change	Price Target Change
Nov-12-24	Initiated	UBS	Buy	$26
Apr-29-24	Downgrade	Guggenheim	Buy → Neutral
Jan-24-24	Initiated	Goldman	Neutral	$13
Mar-22-23	Downgrade	Goldman	Buy → Neutral	$20 → $6
Dec-01-22	Initiated	Goldman	Buy	$20
Dec-29-21	Resumed	Jefferies	Buy	$30
Jun-02-21	Initiated	H.C. Wainwright	Buy	$35
Feb-11-21	Initiated	Guggenheim	Buy	$36
Dec-14-20	Initiated	Jefferies	Buy	$25
Nov-12-20	Reiterated	B. Riley Securities	Buy	$31 → $28
Sep-25-20	Initiated	B. Riley FBR	Buy	$31
Aug-14-20	Initiated	Evercore ISI	Outperform
Jul-31-20	Initiated	Piper Sandler	Overweight	$80
Jul-28-20	Initiated	JMP Securities	Mkt Outperform	$50
Feb-24-20	Resumed	ROTH Capital	Buy	$13
Jul-19-19	Initiated	ROTH Capital	Buy	$8.30
Oct-09-17	Initiated	Piper Jaffray	Overweight	$6

Show Previous Ratings

Nov-26-24 07:30AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
Nov-15-24 11:00AM	Altimmune Presents New Data on the Effect of Pemvidutide on Inflammatory Lipids in Subjects with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) at The Liver Meeting 2024 (GlobeNewswire) -9.99%
Nov-12-24 07:00AM	Altimmune Announces Third Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire) +29.12%
Nov-11-24 07:30AM	Altimmune Appoints Life Sciences Industry Veteran Greg Weaver as Chief Financial Officer (GlobeNewswire)
07:30AM	Altimmune Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
07:30AM	Loading…
Nov-07-24 07:30AM	Altimmune Announces Successful Completion of End-of-Phase 2 Meeting with FDA for Pemvidutide in the Treatment of Obesity (GlobeNewswire)
Nov-06-24 07:30AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
Nov-04-24 07:30AM	Altimmune to Report Third Quarter 2024 Financial Results and Provide Business Update on November 12, 2024 (GlobeNewswire)
Oct-15-24 08:00AM	Altimmune to Present New Data on the Lipidomic Profile in Subjects Treated with Pemvidutide at The Liver Meeting 2024 (GlobeNewswire) +9.49%
Oct-01-24 07:30AM	Altimmune to Participate in the H.C. Wainwright 8th Annual MASH Virtual Conference (GlobeNewswire)
Sep-30-24 07:30AM	Altimmune Completes Enrollment in Phase 2b IMPACT Trial of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH) (GlobeNewswire) -5.10%
Sep-10-24 01:09PM	CORRECTION Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes (GlobeNewswire) +9.09%
07:45AM	Altimmune Presents Results of a Phase 2 MRI-Based Body Composition Sub-Study at 60th Annual Meeting of the European Association for the Study of Diabetes (GlobeNewswire)
Sep-03-24 07:30AM	Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 60th Annual Meeting of the European Association for the Study of Diabetes (GlobeNewswire)
Aug-08-24 07:00AM	Altimmune Announces Second Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire) +15.09%
07:00AM	Loading…
Aug-07-24 07:00AM	CytoSorbents to Report Second Quarter 2024 Operating and Financial Results (GlobeNewswire) -7.02%
Aug-01-24 07:30AM	Altimmune to Report Second Quarter 2024 Financial Results and Provide Business Update on August 8, 2024 (GlobeNewswire)
Jul-25-24 07:30AM	Altimmune Announces Publication of Clinical Study of Pemvidutide in Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) in Journal of Hepatology (GlobeNewswire) +6.70%
Jul-09-24 06:42AM	7 Bullish Stock Picks With the Potential to Turn $5K Into $50K (InvestorPlace)
Jul-06-24 08:00AM	The 7 Best Under $10 Stocks to Buy in July 2024 (InvestorPlace)
Jul-02-24 07:30AM	Altimmune to Participate at Leerink Partners Therapeutics Forum (GlobeNewswire) -6.39%
Jun-28-24 10:09AM	The 3 Smartest Biotech Stocks to Buy With $5K Right Now (InvestorPlace)
01:55AM	Altimmune, Inc. (ALT): Why Are Hedge Funds Shorting This Biopharmaceutical Stock? (Insider Monkey)
Jun-26-24 11:08PM	What Is Short Selling In Stock Market? 15 Stocks Hedge Funds are Shorting (Insider Monkey) -15.59%
07:30AM	Altimmune Mourns Passing of Chief Financial Officer, Richard Eisenstadt (GlobeNewswire)
Jun-24-24 06:02PM	Crypto under pressure, Good Buy or Goodbye: Market Domination (Yahoo Finance Video) +11.39%
03:52PM	Altimmune reports positive results in weight-loss drug trial (Yahoo Finance Video)
11:13AM	BITF Stock Alert: Riot Platforms Is Changing Its Approach to Take Over Bitfarms (InvestorPlace)
10:56AM	ALT Stock Alert: Altimmune Pops on Weight-Loss Drug Findings (InvestorPlace)
Jun-23-24 01:45PM	Altimmune Presents Data from Phase 2 MOMENTUM Trial of Pemvidutide in Obesity during Oral Presentation at the American Diabetes Association's 84th Scientific Sessions (GlobeNewswire)
04:45PM	Loading…
Jun-22-24 04:45PM	Altimmune Presents Data on the Effect of Pemvidutide on Cardioinflammatory Lipids during Oral Presentation at American Diabetes Association's 84th Annual Scientific Sessions (GlobeNewswire)
Jun-21-24 05:45AM	Altimmune, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your Rights - ALT (PR Newswire) +7.91%
Jun-20-24 07:30AM	Altimmune to Participate in the Piper Sandler 2nd Annual Virtual Obesity Investor Day to Discuss ADA Takeaways (GlobeNewswire)
Jun-18-24 07:30AM	Altimmune Announces Oral Presentations of Pemvidutide Clinical Data at Upcoming American Diabetes Association's Scientific Sessions (GlobeNewswire)
Jun-12-24 10:00AM	3 Stocks Quietly Preparing for a 10X Surge: June Edition (InvestorPlace)
Jun-05-24 07:00AM	Altimmune Presents Data at EASL International Liver Congress 2024 Supporting the Disease Modifying Potential and Differentiated Therapeutic Profile of Pemvidutide in Metabolic Dysfunction-Associated Steatohepatitis (MASH) (GlobeNewswire)
Jun-04-24 06:00AM	The 3 Most Undervalued Biotech Stocks to Buy in June 2024 (InvestorPlace)
May-29-24 07:31AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
07:30AM	Altimmune to Present Clinical Data from Pemvidutide at Upcoming EASL International Liver Congress 2024 (GlobeNewswire)
May-27-24 02:56PM	The Penny Stock Prophecy: 3 Overlooked Stocks Primed to Pop (InvestorPlace)
May-23-24 05:45AM	Altimmune, Inc. Sued for Securities Law Violations - Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your Rights - ALT (PR Newswire) -6.34%
May-21-24 02:53PM	Altimmune, Inc. Sued for Securities Law Violations Investors Should Contact Levi & Korsinsky for More Information ALT (GlobeNewswire)
09:00AM	Roundhill Investments Launches GLP-1 & Weight Loss ETF (OZEM) (PR Newswire)
May-20-24 03:01PM	Robbins LLP Urges Altimmune, Inc. (ALT) Stockholders With Large Losses to Contact the Firm for Information About Their Rights (Business Wire)
May-17-24 06:15AM	Wall Street Favorites: 3 Biotech Stocks with Strong Buy Ratings for May 2024 (InvestorPlace) -10.00%
May-15-24 05:45AM	Altimmune, Inc. Sued for Securities Law Violations - Investors Should Contact Levi & Korsinsky for More Information - ALT (PR Newswire) +13.43%
May-14-24 12:47PM	Shareholders of Altimmune, Inc. Should Contact Levi & Korsinsky Before July 5, 2024 to Discuss Your Rights ALT (GlobeNewswire) +6.11%
May-10-24 03:58PM	Altimmune, Inc. (NASDAQ:ALT) Q1 2024 Earnings Call Transcript (Insider Monkey) -6.48%
May-09-24 11:57AM	ALT Stock Earnings: Altimmune Beats EPS for Q1 2024 (InvestorPlace) +7.82%
07:00AM	Altimmune Announces First Quarter 2024 Financial Results and Provides a Business Update (GlobeNewswire)
May-08-24 08:50AM	Altimmune, Inc. Investors Who Have Lost Money Should Contact Block & Leviton to Find Out How They Might Recover Money Through A Recent Securities Lawsuit (GlobeNewswire)
May-07-24 07:30AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
May-02-24 07:30AM	Altimmune to Report First Quarter 2024 Financial Results and Provide Business Update on May 9, 2024 (GlobeNewswire)
May-01-24 07:30AM	Altimmune to Participate at Two Upcoming Conferences (GlobeNewswire) +7.94%
Apr-25-24 05:24PM	Altimmune Statement on the Passing of Dr. Stephen Harrison (GlobeNewswire)
Mar-29-24 12:00PM	Altimmune (ALT) Moves to Buy: Rationale Behind the Upgrade (Zacks)
Mar-28-24 10:49AM	Altimmune, Inc. (NASDAQ:ALT) Q4 2023 Earnings Call Transcript (Insider Monkey) +14.51%
Mar-27-24 06:29PM	A Novo Nordisk competitor teased a weight loss drug that minimizes muscle loss seen in other drugs (Quartz)
11:53AM	ALT Stock Earnings: Altimmune Beats EPS for Q4 2023 (InvestorPlace)
07:58AM	Altimmune bails on hepatitis B after phase 2 data disappoint, quashing partnering plans (FierceBiotech.com)
07:00AM	Altimmune Announces Positive Lean Mass Preservation Data for Pemvidutide and Reports Fourth Quarter and Full Year 2023 Financial Results (GlobeNewswire)
Mar-20-24 07:30AM	Altimmune to Report Fourth Quarter and Full Year 2023 Financial Results and Provide Business Update on March 27, 2024 (GlobeNewswire) +6.86%
Feb-26-24 09:26AM	Why Is Altimmune (ALT) Stock Up 14% Today? (InvestorPlace) +23.04%
Feb-20-24 10:26AM	Altimmune (ALT) to Report Q4 Earnings: What's in the Cards? (Zacks)
Feb-13-24 03:07PM	Kerrisdale Capital Slams Altimmune (ALT) Stock in New Short Report (InvestorPlace) -18.65%
Jan-02-24 07:30AM	Altimmune Announces Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 6, 2024 (GlobeNewswire) -6.49%
Dec-01-23 11:45AM	Why Is Altimmune (ALT) Stock Up 43% Today? (InvestorPlace) +12.97%
04:47AM	Altimmune, seeking edge on Lilly and Novo, puts heart health at center of phase 2 obesity data drop (FierceBiotech.com)
Nov-30-23 04:24PM	Altimmune Announces Positive Topline Results from MOMENTUM 48-Week Phase 2 Obesity Trial of Pemvidutide (GlobeNewswire)
Nov-08-23 09:15AM	Altimmune, Inc. (NASDAQ:ALT) Q3 2023 Earnings Call Transcript (Insider Monkey)
Nov-07-23 07:00AM	Altimmune Announces Third Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Oct-31-23 07:30AM	Altimmune to Report Third Quarter 2023 Financial Results and Provide Business Update on November 7, 2023 (GlobeNewswire)
Oct-26-23 07:30AM	Altimmune Granted Fast Track Designation by FDA for Pemvidutide for the Treatment of Non-Alcoholic Steatohepatitis (NASH) (GlobeNewswire)
Oct-25-23 07:30AM	Altimmune to Present New Data on the Anti-Inflammatory and Anti-Fibrotic Properties of Pemvidutide in a Late-Breaking Presentation at The Liver Meeting 2023 (GlobeNewswire)
Oct-17-23 07:30AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
Sep-26-23 07:30AM	Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at 59th Annual Meeting of the European Association for the Study of Diabetes (GlobeNewswire)
Sep-12-23 07:30AM	Altimmune Announces Completion of Dosing in the Phase 2 MOMENTUM Trial of Pemvidutide in Subjects with Obesity or Overweight (GlobeNewswire) +7.41%
Aug-30-23 07:30AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
Aug-10-23 07:00AM	Altimmune Announces Second Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire)
Aug-03-23 07:30AM	Altimmune to Report Second Quarter 2023 Financial Results and Provide Business Update on August 10, 2023 (GlobeNewswire)
Aug-01-23 07:30AM	Altimmune Announces Initiation of Phase 2b IMPACT Trial Evaluating the Efficacy and Safety of Pemvidutide in Non-Alcoholic Steatohepatitis (NASH) (GlobeNewswire)
Jun-27-23 09:56AM	These 2 Strong Buy Penny Stocks Could Soar to $25 (Or Higher), Says Piper Sandler (TipRanks) +6.96%
Jun-16-23 07:30AM	Altimmune to Participate in the Healthcare Virtual Conference Presented by Maxim Group LLC and hosted by M-Vest on Tuesday, June 20th, 2023 (GlobeNewswire)
Jun-15-23 07:30AM	Altimmune Announces Oral Presentation of Pemvidutide Clinical Data in Treatment of NAFLD at Upcoming EASL International Liver Congress 2023 (GlobeNewswire)
May-31-23 07:30AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
May-11-23 07:00AM	Altimmune Announces First Quarter 2023 Financial Results and Provides a Business Update (GlobeNewswire) +7.03%
May-08-23 07:30AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire)
May-04-23 07:30AM	Altimmune to Report First Quarter 2023 Financial Results and Provide Business Update on May 11, 2023 (GlobeNewswire)
Apr-11-23 07:30AM	Altimmune Completes Enrollment in Phase 2 Clinical Trial of HepTcell, an Immunotherapeutic for Chronic Hepatitis B (GlobeNewswire)
Mar-27-23 04:05PM	Altimmune Appoints Former GSK Executive Catherine Angell Sohn, Pharm.D. to its Board of Directors (GlobeNewswire) +11.57% -8.30%
Mar-21-23 07:00AM	Altimmune Announces Positive Results from Week 24 Interim Analysis of Pemvidutide MOMENTUM Phase 2 Obesity Trial and 12-Week Phase 1b Type 2 Diabetes Safety Trial (GlobeNewswire) -54.67%
Feb-28-23 07:00AM	Altimmune Announces Fourth Quarter and Full Year 2022 Financial Results and Provides a Business Update (GlobeNewswire) +6.42%
Feb-21-23 07:30AM	Altimmune to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Business Update on February 28, 2023 (GlobeNewswire) -5.27%
Jan-04-23 07:30AM	Altimmune Appoints Raymond Jordt as Chief Business Officer (GlobeNewswire) -5.25%
07:30AM	Altimmune Announces Oral Presentation of Pemvidutide Clinical Data at Upcoming NASH-TAG Conference on January 7, 2023 (GlobeNewswire)
Dec-20-22 07:00AM	Altimmune Announces Positive Topline Results from 24-Week (12-Week Extension) Trial of Pemvidutide in Subjects with Non-Alcoholic Fatty Liver Disease (NAFLD) (GlobeNewswire) +15.98%
Nov-22-22 07:30AM	Altimmune to Participate at Two Upcoming Investor Conferences (GlobeNewswire) +6.52%
Nov-10-22 07:00AM	Altimmune Announces Third Quarter 2022 Financial Results and Provides a Business Update (GlobeNewswire) +9.18%
Nov-03-22 07:30AM	Altimmune to Report Third Quarter 2022 Financial Results and Provide Business Update on November 10 (GlobeNewswire)
Oct-28-22 07:30AM	Altimmune to Present Pemvidutide Clinical Data at the Upcoming AHA Scientific Sessions and AASLD The Liver Meeting® (GlobeNewswire)

Altimmune, Inc. is a clinical stage biopharmaceutical company, which focuses on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company's lead product candidate, pemvidutide, is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of obesity and NASH. In addition, Altimmune is developing HepTcell, an immunotherapeutic designed to achieve a functional cure for chronic hepatitis B. The company was founded in 1997 and is headquartered in Gaithersburg, MD.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Drutz David	Director	Aug 19 '24	Option Exercise	2.55	41,750	106,375	63,708	Aug 20 06:05 PM
Drutz David	Director	Aug 19 '24	Sale	6.90	16,011	110,547	41,958	Aug 20 06:05 PM
Roberts M Scot	Chief Scientific Officer	Feb 02 '24	Option Exercise	0.00	7,775	0	44,990	Feb 05 06:02 PM
Roberts M Scot	Chief Scientific Officer	Feb 01 '24	Option Exercise	0.00	6,166	0	39,016	Feb 05 06:02 PM
Harris Matthew Scott	Chief Medical Officer	Feb 02 '24	Option Exercise	0.00	7,775	0	55,965	Feb 05 06:01 PM
Harris Matthew Scott	Chief Medical Officer	Feb 01 '24	Option Exercise	0.00	6,166	0	49,991	Feb 05 06:01 PM
Garg Vipin K	President and CEO	Feb 02 '24	Option Exercise	0.00	18,950	0	300,404	Feb 05 06:00 PM
Garg Vipin K	President and CEO	Feb 01 '24	Option Exercise	0.00	16,545	0	288,767	Feb 05 06:00 PM
Roberts M Scot	Chief Scientific Officer	Jan 30 '24	Option Exercise	0.00	9,275	0	29,699	Feb 01 06:03 PM
Harris Matthew Scott	Chief Medical Officer	Jan 30 '24	Option Exercise	0.00	9,275	0	43,277	Feb 01 06:01 PM
Garg Vipin K	President and CEO	Jan 30 '24	Option Exercise	0.00	26,775	0	276,030	Feb 01 06:01 PM
Eisenstadt Richard I	Chief Financial Officer	Jan 30 '24	Option Exercise	0.00	9,275	0	42,566	Feb 01 06:00 PM
Jordt Raymond M	Chief Business Officer	Jan 01 '24	Option Exercise	0.00	9,375	0	11,207	Jan 04 06:00 PM
Eisenstadt Richard I	Chief Financial Officer	Dec 29 '23	Option Exercise	0.00	12,500	0	36,335	Jan 02 06:00 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

ALT

Altimmune Inc

Upgrade your FINVIZ experience